Cannabinoids - U.S. Patents

Cannabinoid Patents






Cannabichromene (CBC)

Indication: Antiinflammatory and antimicrobial compounds and compositions

US Patent No: US 4,837,228 A

Filing Date:  Jun 6, 1989

The use of cannabichromene (CBC) and its homologues and isomers to induce hypothermia, reduce inflammation in mammals, and as antimicrobial agents is disclosed. Preferably, a compound selected from cannabichromene, its homologues and isomers, is administered as a novel composition, in combination with a pharmaceutically acceptable diluent carrier.

PDF of Patent:


Indication: A method of treating glaucoma

U.S. Patent No: US 4,189,491 A

Filing Date: Feb 19, 1980

Significant success in alleviating the symptoms of glaucoma is achieved by orally administering to a glaucoma sufferer a therapeutically effective, but sub-psychotropic dose of tetrahydrocannabinol (THC), which is the most active ingredient in marijuana. The most significant results are achieved when this form of treatment is combined with conventional types of anti-glaucoma treatment, although in a limited number of cases, THC therapy alone proved successful. Also disclosed is a dosage unit form for THC comprising a suitable dose of THC in combination with an innocuous diluent such as fructose.

PDF of Patent:

Anandamide Compounds

Indication: Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same

U.S. Patent No: US 5,631,297 A

Filing Date:  May 20, 1997

Anandamides useful for the treatment of intraocular hypertension, as well as ophthalmic compositions comprising the same and a cyclodextrin, and methods of use of these compounds to treat intraocular hypertension.

PDF of Patent:

Transcutaneous application of marijuana

Indication: Pain, inflammation and arthritis

​U.S. Patent No: US 6,132,762 A

Filing Date:

A transcutaneous therapeutic formulation comprising marijuana and a carrier for the treatment of pain, inflammation, arthritis and related disorders in humans and animals.

PDF of Patent:

Cannabidiol and inflammatory diseases

Use of cannabinoids as anti-inflammatory agents

US Patent No: US 6,410,588 B1

Filing Date:

The application relates to the identification that cannabinoids, such as cannabidiol can be used to treat inflammatory diseases. Cannabinoids for use in treating inflammatory diseases, methods of treating inflammatory diseases and cannabinoids in combination with pharmaceutically acceptable carriers are claimed.

PDF of Patent:

Treatment for coughs

Treatment for cough

US Patent No: US 6,974,568 B2

Filing Date: 

The invention discloses the existence of cannabinoid receptors in the airways, which are functionally linked to inhibition of cough. Locally acting cannabinoid agents can be administered to the airways of a subject to ameliorate cough, without causing the psychoactive effects characteristic of systemically administered cannabinoids. In addition, locally or systemically administered cannabinoid inactivation inhibitors can also be used to ameliorate cough. The present invention also defines conditions under which cannabinoid agents can be administered to produce anti-tussive effects devoid of bronchial constriction.

PDF of Patent:

Inflammatory and autoimmune diseases

​Strokes, Alzheimer's and Parkinson's

Cannabinoids as ​antioxidants and neuroprotectants

US Patent No: US 6,630,507 B1

Filing Date: 

Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3.

PDF of Patent:

Novel polycyclic cannabinoid analogs

Dibenzo[b,d]pyran-6-ones used for providing a physiological effect to treat pain, pain associated with cancer, chemotherapy, neuropathy, Multiple Sclerosis, Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and inflammation; antinociceptive agents

US Patent No: US 7741365 B2

Filing Date:

Novel polycyclic cannabinoid analogs are presented which have preferentially high affinities for the cannabinoid CB2 receptor sites.

PDF of Patent:

Prostate cancer and prostatitis

aqueous extract of finely chopped dried selenium- and zinc-enhanced cannabis (Cannabis indicaxCannabis ruderalis), chopped shiitake mushrooms (Lentinula edodes), and chopped maitake mushrooms (Grifola frondosa) packaged in a cellulose capsule for oral adminstration to treat prostatitis, prostate cancer

US Patent No: US 7,597,910 B2

Filing Date:

Compositions and methods are described for the treatment of prostatitis, benign prostatic hypertrophy, and prostate cancer. The compositions contain either aqueous extracts or dried mixtures of selenium- and zinc-enriched cannabis plant material, shiitake mushrooms, and maitake mushrooms. The compositions are effective in treating prostate disorders by alleviating pain and voiding symptoms, decreasing inflammation and prostate size, reducing cellular proliferation in prostate tissue, and/or reducing PSA levels to within the normal range of 0-4.

PDF of Patent:

Detecting traces of cannabinoids

Oral detection test for cannabinoid use

US Patent No: US 7,977,107 B2

Filing Date:

A method for confirming the active intake of marijuana and its active component Δ9-tetrahydrocannabinol (“Δ9-THC”) by detecting the amount of 11-nor-Δ9-THC carboxylic acid (“THCA”) in oral fluid at the picogram per milliliter (pg/ml) level using chromatography/mass spectrometry/mass spectrometry (“GC/MS/MS”).

PDF of Patent:

Diabetes and insulitis

Treating or preventing diabetes with cannabidiol

US Patent No: US 8,071,641 B2

Filing Date:

Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.

PDF of Patent:

Cannabidiol and autoimmune hepatitis

Use of cannabidiol in the treatment of autoimmune hepatitis

US Patent No: US 8,242,178 B2

Filing Date:

Methods of treating autoimmune hepatitis are provided. The methods include injecting cannabidiol into the subject, where the cannabidiol is synthetic cannabidiol or natural cannabidiol isolated from other natural cannabinoids.

PDF of Patent:

Nausea, vomiting and motion sickness

cannabis extract; containing a pharmaceutically acceptable amount of CBD and/or CBDA and/or the propyl variants CBDV and/or CBDVA

US Patent No: US 8,034,843 B2

Filing Date:

Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use.

PDF of Patent:

Cannabigerol (CBG)

Therapeutic uses of cannabigerol

US Patent No:US 20100292345 A1

Filing Date:

The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.

PDF of Patent:

Multiple sclerosis and MS relapse

inter alia, treating and/or preventing symptoms; Spasticity 

US Patent No: US 20080181942 A1

Filing Date:

Methods are provided for, inter alia, treating and/or preventing symptoms associated with multiple sclerosis and MS relapse.

PDF of Patent:

Chronic Obstructive Pulmonary Disease

Pharmaceutical Compositons for the Treatment of Chronic Obstructive Pulmonary Disease

US Patent No: US 20090197941 A1

Filing Date:

The invention relates to the use of a combination of cannabinoids for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Preferably the combination of cannabinoids are cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.

PDF of Patent:

Treating cell proliferation and cancers

Methods and compositions for treating cancer

US Patent No: US 20100204312 A1

Filing Date: 

This disclosure provides compositions and method useful for treating cell proliferative disorders including cancer. The disclosure provides cannabidiol derivatives and compositions thereof either alone or in combination with THC or a derivative thereof.

PDF of Patent:

Inhibition of tumour cell migration

Administering cannabidiol produced from a given cannabis chemovar and in the form of a botanical drug substance; modulators motility of glioma cell motility; uneffected by involvement of cannabinoid receptor antagonists; antitumor, anticarcinogenic, antiproliferative and antimetastsis agents.

US Patent No: 20080262099 A1

Filing Date:

The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration.

PDF of Patent:

Gastrointestinal inflammatory and cancers

Composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases

US Patent No: US 20100222437 A1

Filing Date:

The invention relates to a composition comprising cannabidiol and Denbinobin and its use in medicine, for example, for the prevention and treatment of gastrointestinal inflammatory diseases and for the prevention and treatment of gastrointestinal cancers.

PDF of Patent:

This Research and Resources page is sponsored by the Ohio Rights Group Education Fund.
Please support our charitable and educational work by making a generous tax deductible donation.